According to the latest analysis, the average forward P/E ratio of the S&P 500 index has reached 21.5 times, significantly higher than the 17.6 times of a decade ago. In a market environment with high valuations, finding investment targets with a margin of safety is challenging, but there are still some undervalued dividend aristocrats worth investors’ attention. The following two companies not only have attractive valuations but also offer substantial cash returns.
As a leading midstream energy company in North America, Enterprise Products Partners has built a complete asset matrix ranging from pipeline networks and storage facilities to deepwater docks. Compared to the highly volatile upstream exploration and development and downstream retail sectors, the midstream business, with its long-term service contract model, exhibits unique defensive attributes—by transporting rather than extracting or selling energy products, it effectively avoids the risks of commodity price fluctuations.
The advantages of this business model are directly reflected in the financial data: the company consistently maintains a net profit margin of over 10%. Its strong operating cash flow not only ensures dividend payments but also supports annual capital expenditures averaging $2.5 billion to $2.9 billion, continuously widening its income moat. It is worth noting that despite a recent rebound in its stock price, the stock’s forward P/E ratio is still just over 13 times, with a corresponding dividend yield of nearly 5.9%. This yield level is more than five times the average of S&P 500 components.
In the capital-intensive pharmaceutical industry, business transformation is never easy. Bristol Myers Squibb long relied on two flagship products, the multiple myeloma drug Revlimid and the anticoagulant Eliquis. However, Eliquis is now facing a patent cliff, and Revlimid has recently lost its patent protection entirely. These two drugs are now classified under the “legacy product portfolio,” and their revenue contributions are no longer what they once were.
To address the patent expiration crisis, the company is vigorously cultivating a “growth product portfolio” centered on the cancer drug Opdivo. The fourth-quarter 2025 earnings report shows that revenue from the patent-protected new drug portfolio grew 16% year-over-year, but a 15% revenue decline in the legacy product line partially offset this growth momentum, resulting in a modest 1% year-over-year increase in total revenue for the quarter. This transformation pain has precisely created a valuation gap: currently, the stock’s forward P/E ratio is less than 10 times. For a pharmaceutical giant that holds multiple blockbuster drugs and consistently pays dividends, such a valuation appears overly pessimistic. The current dividend yield of 4.2% makes it a target of interest for value investors.
